Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical Inc. has recently enhanced its financial position through multiple equity financings and an increase in financing income, which rose to $284K for the quarter compared to $85K in the previous year, underlining improved interest earnings from marketable securities. The company is strategically preparing for its full product launch in the U.S. and Europe, bolstering its commercial capabilities and gathering positive feedback from providers, which positions the LIBERTY Endovascular Robotic System favorably in the market. As a result of these factors, Microbot Medical is expected to experience significant growth momentum and increased operational readiness leading up to key product launches scheduled in the coming years.

Bears say

Microbot Medical faces significant challenges that contribute to a negative outlook on its stock, including delays in the commercialization of its LIBERTY Endovascular Robotic System and potential difficulties in expanding into neuro and cardio markets. Additionally, the company is experiencing a lack of profitability in the near term, compounded by reimbursement headwinds and the erosion of hospital margins due to device costs. The absence of data from randomized controlled trials and the uncertainty surrounding international regulatory approvals further exacerbate the risks related to market adoption and financial performance.

Microbot Medical (MBOT) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Dec 24, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.